Jack Puymirat
- Formation
- à venir
Aucune offre active
Autres opportunités de carrière
- Axe principal
- Neurosciences
- Adresse
- 2705, boulevard Laurier, RC-9300
Québec (Québec)
CANADA G1V 4G2 - Téléphone
- +1 418-525-4444, poste 42186
- Télécopieur
- +1 418-654-2753
- Courriel
- Jack.Puymirat@crchul.ulaval.ca
Publications récentes (voir toutes les publications de ce chercheur)
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, Chuah M, Cornetta K, Davies KE, Dickson JG, Duchateau P, Flotte TR, Gaudet D, Gersbach CA, Gilbert R, Glorioso J, Herzog RW, High KA, Huang W, Huard J, Joung JK, Liu D, Lochmuller H, Lustig L, Martens J, Massie B, Mavilio F, Mendell JR, Nathwani A, Ponder K, Porteus M, Puymirat J, Samulski J, Takeda S, Thrasher A, Vandendriessche T, Wei Y, Wilson JM, Wilton SD, Wolfe JH, Gao G. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular therapy : the journal of the American Society of Gene Therapy,
2013. 21: 266-8
Zhao J, Dupre N, Puymirat J, Chahine M. Biophysical characterization of M1476I, a sodium channel founder mutation associated with cold-induced myotonia in French Canadians. The Journal of physiology,
2012. 590: 2629-44
Huguet A, Medja F, Nicole A, Vignaud A, Guiraud-Dogan C, Ferry A, Decostre V, Hogrel JY, Metzger F, Hoeflich A, Baraibar M, Gomes-Pereira M, Puymirat J, Bassez G, Furling D, Munnich A, Gourdon G. Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1,000 CTG Repeats from the Human DM1 Locus. PLoS genetics,
2012. 8: e1003043
Beaulieu D, Thebault P, Pelletier R, Chapdelaine P, Tarnopolsky M, Furling D, Puymirat J. Abnormal prostaglandin E2 production blocks myogenic differentiation in myotonic dystrophy. Neurobiology of disease,
2012. 45: 122-9
Hiba B, Richard N, Hebert LJ, Cote C, Nejjari M, Vial C, Bouhour F, Puymirat J, Janier M. Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. Journal of magnetic resonance imaging : JMRI,
2012. 35: 678-85
Puymirat J, Bouchard JP, Mathieu J. Efficacy and Tolerability of a 20-mg Dose of Methylphenidate for the Treatment of Daytime Sleepiness in Adult Patients With Myotonic Dystrophy Type 1: A 2-Center, Randomized, Double-Blind, Placebo-Controlled, 3-Week Crossover Trial. Clinical therapeutics,
2012. 34: 1103-11
Cote C, Hiba B, Hebert LJ, Vial C, Remec JF, Janier M, Puymirat J. MRI of tibialis anterior skeletal muscle in myotonic dystrophy type 1. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
2011. 38: 112-8
Bassez G, Puymirat J. Registres des dystrophies myotoniques : une collaboration franco-québécoise Les Cahiers de Myologie,
2011. 16: 17-18
Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, Butler-Browne G, Puymirat J, Gourdon G, Furling D. Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway. Neuromuscular disorders : NMD,
2010. 20: 319-25
Hebert LJ, Remec JF, Saulnier J, Vial C, Puymirat J. The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study. BMC musculoskeletal disorders,
2010. 11: 72
